SlideShare a Scribd company logo
1 of 44
DRUG DISTRIBUTION
Asnake W.(B.Pharm, MSc in Pharmaceutics)
DRUG DISTRIBUTION…
 Is reversible transfer of a drug to and from the
site of measurement (blood or plasma).
 It is the passage of drug from the circulation to
the tissue and site of its action.
 Low plasma binding or high tissue binding or
high lipophilicity usually means an extensive
tissue distribution
5/7/2024
Phar 412 by Asnake W. (B Phar, MSc)
2
DRUG DISTRIBUTION…
5/7/2024
Phar 412 by Asnake W. (B Phar, MSc)
3
 In pharmacokinetics, the distribution is described by the
parameter V, the apparent volume of distribution.
 Volume of plasma in which the total amount of drug in the body
would be required to be dissolved in order to reflect the drug
concentration attained in plasma.
Affects
The half life of the drug and
The fluctuation of the concentration at steady
state.
Factors affecting drug distribution
5/7/2024
Phar 412 by Asnake W. (B Phar, MSc)
4
 Extent/rate of drug distribution
1. Membrane permeability
2. Blood perfusion
3. Lipid solubility
4. PH-PKA
5. Plasma protein binding
6. Tissue drug binding
Factors affecting drug distribution
5/7/2024
Phar 412 by Asnake W. (B Phar, MSc)
5
1.Membrane permeability
 Capillary walls are quite permeable
 Lipid soluble drugs pass through very rapidly
 Water soluble compounds penetrate more slowly at a
rate more dependent on their size.
Plasma membrane barrier and drug diffusion across it
Factors affecting drug distribution
5/7/2024
Phar 412 by Asnake W. (B Phar, MSc)
6
 There are deviations to the typical capillary structure
I. Permeability is greatly increased in the renal capillaries
- by pores in the membrane of the endothelial cells,
II. in specialized hepatic capillaries, known as sinusoids
-may lack a complete lining.
results in more extension distribution of many drugs
Factors affecting drug distribution
5/7/2024
Phar 412 by Asnake W. (B Phar, MSc)
7
III. Brain capillaries
 restrict the transfer of molecules from blood to brain
tissue.
 Lipid soluble compounds can be readily transferred
 This is the basis of the "blood-brain“ barrier.
Thiopental vs pencillin, Levodopa vs dopamine
5/7/2024
Phar 412 by Asnake W. (B Phar, MSc)
8
2. Blood perfusion rate
The rate at which blood perfuses to different organs varies
widely
Factors affecting drug distribution…
Factors affecting drug distribution…
5/7/2024
Phar 412 by Asnake W. (B Phar, MSc)
9
3.Lipid Solubility
 Lipid solubility will affect the ability of the drug to cross
lipid membrane barriers
 Very high lipid solubility can result in a drug partitioning
into highly vascular lipid-rich areas.
 these drugs slowly redistribute from body fat where they
may remain for long periods of time.
Factors affecting drug distribution…
5/7/2024
Phar 412 by Asnake W. (B Phar, MSc)
10
4. Effects of pH
 The rate of movement of a drug out of circulation will
depend on its degree of ionization and therefore its pKa.
 Changes in pH occurring in disease may also affect drug
distribution.
E.g. blood becomes more acidic if respiration is
inadequate.
 Barbiturate poisoning treated by Sodium bicarbonate
5.Plasma protein binding:
 Extensive plasma protein binding will cause more drug to
stay in the central blood compartment.
 ↑Strong proteinbinding=↓V
Blood proteins to which drugs bind
5/7/2024
Phar 412 by Asnake W. (B Phar, MSc)
11
Protein Molecular
Weight
Concentration (g%) Drugs that bind
Human Serum
Albumin
65,000 3.5-5.0 Large variety of drugs
a1-Acid
Glycoprotein
44,000 0.04-0.1 Basic drugs such as
imipramine, lidocaine,
quinidine, etc.
Lipoproteins 200,000 to
3,400,000
Variable Basic, lipophilic drugs like
chlorpromazine
a1-Globulin 59,000 0.003-0.007 Steroids like corticosterone,
and thyroxine and
cyanocobalamin
a2-Globulin 1,34,000 0.015-0.06 Vitamins A, D, E and K and
cupric ions
Haemoglobin 64,500 11-16 Phenytoin, pentobarbital, and
phenothiazines
Factors affecting drug distribution…
5/7/2024
Phar 412 by Asnake W. (B Phar, MSc)
12
What is the effect of protein binding on drug
action?
Extensive plasma protein binding will...decrease peak
plasma level.
 Elimination of a highly bound drug may be delayed
-drug elimination by metabolism and excretion will be
delayed.
responsible for prolonging the effect of the drug
Factors affecting drug distribution…
5/7/2024
Phar 412 by Asnake W. (B Phar, MSc)
13
 A low plasma protein level may occur in:
-old age
-malnutrition
 Illness such as liver disease, chronic renal failure where
there is excessive excretion of albumin.
 In each case the result is a smaller proportion of drug in
bound form and more free drug in the plasma.
 able to produce a greater therapeutic effect
Factors affecting drug distribution (Cont.):
5/7/2024
Phar 412 by Asnake W. (B Phar, MSc)
14
6. Tissue drug binding (tissue localization of drugs):
 Drugs may bind to intracellular molecules
 The affinity of a tissue for a drug may be due to: binding
to tissue proteins or to nucleic acids, dissolution in the
lipid
e.g. The concentration of chloroquine in the liver is due to the binding
of the drug to DNA.
e.g. Barbiturates distribute extensively into adipose tissue,
b/c of lipid solubility
e.g. Tetracycline bind to bone thus should be avoided in young children
or discoloration of permanent teeth may occur
(Cont.):
5/7/2024
Phar 412 by Asnake W. (B Phar, MSc)
15
 Other distribution considerations
A. Body composition of the very young and the very old may be
quite different from 'normal’
Eg. Total body water( more in infants), Fat content (elder), BBB( infants),
Plasma protein content ( infants and adults)
A. The obese patients –large adipose tissue than body water
• Drugs which are relatively polar has volume of distribution
values may be lower than normal.
• apparent volume of distribution of antipyrine is 0.62l/kg in normal
weight subjects but 0.46l/kg in obese patients
• digoxin and gentamicin are also quite polar
Drug metabolism
Phar 412 by Asnake W. (B Phar, MSc)
16
Def. The irreversible biotransformation of drug in the body
 Drug metabolism often converts lipophilic chemical
compounds into:
 more hydrophilic, more water soluble
 have their actions decreased (become less effective)
phenytoin to p-hydroxy phenytoin
 increased (become more effective) eg enalapril to
enalaprilat
 Equal activity: eg phenylbutazone to oxyphenbutazone
 May be converted to less toxic or more toxic metabolites
Drug metabolism
5/7/2024
Phar 412 by Asnake W. (B Phar, MSc)
17
Drug metabolism…
5/7/2024
Phar 412 by Asnake W. (B Phar, MSc)
18
 The metabolism of drugs takes place mainly in the liver
(the smooth endoplasmic reticulum of the liver cell).
 However, kidney, lung, intestine and placenta can also
be involved in this process
 Occasionally the metabolite is less water soluble.
 Example is the acetyl metabolite of some of the sulfonamides.
-Precipitated in urine, crystalluria.
Drug metabolism
5/7/2024
Phar 412 by Asnake W. (B Phar, MSc)
19
Drug metabolism
5/7/2024
Phar 412 by Asnake W. (B Phar, MSc)
20
Phases of metabolism:
5/7/2024
Phar 412 by Asnake W. (B Phar, MSc)
21
Phase I reactions:
 Change drugs to more hydrophilic metabolites
-more readily excreted
 Introduce into the drug molecule sites for phase II reactions
 May be less toxic (but not always)
 Mostly occur in the endoplasmic reticulum (microsomes) of
liver cells.
 Usually involve oxidation, reduction, hydrolysis or other
reactions ( Reading assignments)
Phase two reactions
5/7/2024
Phar 412 by Asnake W. (B Phar, MSc)
22
Conjugation
 Conjugation reactions covalently add large, polar
endogenous molecules to parent drug or Phase I
metabolite →inactive and excretable
 (glucuronide, glutathione, sulfate, acetate, amino acids
etc)
 Readly avaliable, can combine easily, in close association with the
microsomal mixed function oxidases
Phases of metabolism…
5/7/2024
Phar 412 by Asnake W. (B Phar, MSc)
23
Glucuronidation
 This is the main conjugation reaction in the body.
-Readily available source of conjugating moiety
-viz. alcohols, acids, amines, etc. can combine easily
-All mammals have the common ability to produce
glucuronides
-The glucuronidation enzymes are in close association with
the microsomal mixed function oxidases
-glucuronidation can take place in most body tissues
Phases of metabolism…
5/7/2024
Phar 412 by Asnake W. (B Phar, MSc)
24
I. Induction
 Induction ~ ↑ metabolic activity of enzyme = ↓ [drug]
E.g. Phenobarbitone will induce the metabolism of itself,
phenytoin, warfarin, etc.
E.g. Cigarette smoking can cause increased elimination of
theophylline.
E.g. alcohol
 Dosing rates may need to be increased to maintain effective
plasma concentrations
Phases of metabolism…
5/7/2024
Phar 412 by Asnake W. (B Phar, MSc)
25
II. Inhibition
 Inhibition ~ ↓ metabolic activity of enzyme = ↑ [drug]
e.g. grape fruit juice
 For example, warfarin inhibits tolbutamide
elimination which can lead to the
accumulation of drug.
 Cimetidine is a therapeutic agent that has been
found to impair the in vivo metabolism of other drugs
Diseases and Drug Metabolism:
5/7/2024 Phar 412 by Asnake W. (B Phar, MSc)
26
Liver Disease:
 Acute or chronic diseases that affect liver function markedly affect
hepatic metabolism of some drugs.
 fat accumulation, alcoholic cirrhosis, biliary cirrhosis, and acute viral
or drug hepatitis.
 may impair hepatic drug-metabolizing enzymes, and thereby
markedly affect drug elimination.
 Eg., The half-life of diazepam inpatients with liver cirrhosis or acute
viral hepatitis is greatly increased, with a corresponding prolongation
of its effect.
Cardiac Disease:
 Cardiac disease, by limiting blood flow to the liver may impair disposition
of those drugs whose metabolism is flow-limited.
Excretion
5/7/2024
Phar 412 by Asnake W. (B Phar, MSc)
27
Excretion…
5/7/2024
Phar 412 by Asnake W. (B Phar, MSc)
28
Excretion
5/7/2024
Phar 412 by Asnake W. (B Phar, MSc)
29
1. Glomerular filtration
2. Active tubular secretion
3. passive tubular reabsorption
1. Glomerular filtration
5/7/2024
Phar 412 by Asnake W. (B Phar, MSc)
30
 In the glomerulus all molecules (including drugs) of
low molecular weight (less than 2000) are radially
filtered out of the blood unless they are tightly
bounded to plasma protein (Albumin).
 GF and ATS tend to increase the concentration of
drugs in lumen and hence facilitate excretion
whereas tubular reabsorption decreases it and
prevents the movement of drug out of the body.
 The driving force is the hydrostatic pressure, 120 to
130 ml/min is filtered through the glomeruli, the
rate being called as the glomerular filtration rate
(GFR).
 Creatinine, inulin, mannitol and sodium
thiosulphate are used to estimate GFR.
2. Active tubular secretion
5/7/2024
Phar 412 by Asnake W. (B Phar, MSc)
31
It is a carrier-mediated process which requires
energy against the for transportation of compounds
against concentration gradient.
The system is capacity-limited and saturable.
System for secretion of organic acids/anions like
penicillins, salicylates, glucuronides, sulphates, and
uric acid are secreted.
System for secretion of organic bases/cations like
morphine, mecamylamine, hexamethonium and
endogenous amines such as catecholamines, choline,
histamine, etc.
Drugs undergoing active secretion have
excretion rate values greater than the normal GFR
value.
3. Tubular reabsorption
5/7/2024
Phar 412 by Asnake W. (B Phar, MSc)
32
 In the distal tubule there is passive
excretion and re-absorption of lipid soluble
drugs.
Filtered lipophilic drugs are extensively
reabsorbed.
Thus if a drug is non-ionized or in the
unionized form it maybe readily reabsorbed.
Many drugs are either weak bases or acids
and therefore the ph of the filtrate can greatly
influence the extent of tubular re absorpation
for many drugs.
Drug excretion
5/7/2024
Phar 412 by Asnake W. (B Phar, MSc)
33
Drug Excretion…
5/7/2024
Phar 412 by Asnake W. (B Phar, MSc)
34
Renal clearance:
 Clearance is defined as the hypothetical volume of body
fluids containing drug from which the drug is removed or
cleared completely in a specific period of time
 quantitatively describing the renal excretion of drugs
 used to investigate the mechanism of drug excretion:
A. if the drug is filtered but not secreted or reabsorbed the
renal clearance will be about 120ml/min in normal subjects.
B. If the renal clearance is less than 120ml/m in then we
can assume that at least two processes are in operation,
glomerular filtration and tubular re-absorption.
C. If the renal clearance is greater than 120ml/m in then
tubular secretion must be contributing to the elimination
process
Drug excretion
5/7/2024
Phar 412 by Asnake W. (B Phar, MSc)
35
Renal drug clearance is lower in:
5/7/2024
Phar 412 by Asnake W. (B Phar, MSc)
36
Elderly and Newborn
Women (20%) than men
Kidney and Heart Disease
Patients taking drugs which block secretion
(aspirin, probenecid)
CONT…
Phar 412 by Asnake W. (B Phar, MSc)
37
2.Fecal excretion:
 Elimination of toxicants in the feces
 Occurs from two processes:
A-excretion in bile:
 Some heavy metals are excreted in the bile, e.g., arsenic,
lead, and mercury.
 However, the most likely substances to be excreted via
the bile are comparatively large, ionized molecules, such
as large molecular weight (greater than 300) conjugates
e.g. morphine and chloramphenicol, indomethacin (as glucuronide,
glutathione).
 The biliary secretion is active
 There can also be competition between compounds
Drug excretion…
Phar 412 by Asnake W. (B Phar, MSc)
38
 Since most of the substances excreted in the bile are
water-soluble not likely to be reabsorbed as such.
 However, enzymes in the intestinal flora
hydrolyzing some glucuronide and sulfate
conjugates less-polar compounds that may
then be reabsorbed.
 This process is known as the entero-hepatic
circulation.
prolong the life of the drug in the body
Drug excretion…
5/7/2024
Phar 412 by Asnake W. (B Phar, MSc)
39
 Another way that drugs can be eliminated via the feces is
by:
B-direct intestinal excretion:
 Orally administered drugs may be excreted in the feces if
they are incompletely absorbed or not absorbed at all
(e.g. Cholestyramine)
 Increasing the lipid content of the intestinal tract can
enhance intestinal excretion of some lipophilic
substances.
Drug excretion…
5/7/2024
Phar 412 by Asnake W. (B Phar, MSc)
40
 For this reason, mineral oil is some times added to the
diet to help eliminate toxic substances, which are known
to be excreted directly into the intestinal tract
 Drugs may be excreted by passive diffusion from:
3.Pulmonary excretion:
 The lung is the major organ of excretion for gaseous and
volatile substances.
 Most of the gaseous anesthetics are extensively
eliminated in expired air.
4.Salivary excretion
5/7/2024
Phar 412 by Asnake W. (B Phar, MSc)
41
 Drug excretion into saliva appears to be dependent on
pH partition and protein binding.
 Basic drugs are excreted more in saliva as compared to
acidic drugs
e.g. caffeine, theophylline, phenytoin, carbamazepine,
etc
 In some instances, salivary secretion is responsible for
localized side effects
Drug excretion
5/7/2024
Phar 412 by Asnake W. (B Phar, MSc)
42
 E.g. Excretion of antibiotics may cause black hairy
tongue,
-Super infection from antibiotics.
-Dental mottling upon tetracycline ingestion.
5.Skin excretion:-
is responsible to some extent for the urticaria and
dermatitis and other hypersensitivity reactions.
Iodine, bromine, benzoic acid, salicylic acid, lead, arsenic
mercury, iron and alcohol are examples of compounds that
excreted in sweat
Drug excretion…
5/7/2024
Phar 412 by Asnake W. (B Phar, MSc)
43
6. Mammary excretion:
 Both a-basic substances and lipid-soluble compounds
can be excreted into milk.
-milk is more acidic than blood plasma.
-milk contains 3-4% lipids,
 lipid-soluble drugs can diffuse along with fats from plasma
into the mammary gland.
 Substances that are chemically similar to calcium can
also be excreted into milk along with calcium
 Ethanol and tetracycline enter the milk by diffusion
through membrane pores( of mammary alveolar cells).
 some potent drugs such as barbiturates, morphine and
ergotamine may induce toxicity in infants
Ends & ???
5/7/2024
Phar 412 by Asnake W. (B Phar, MSc)
44

More Related Content

Similar to Biopharm drug distribution.slideshare ppt

Distribution of drugs Pharmacokinetics
Distribution of drugs PharmacokineticsDistribution of drugs Pharmacokinetics
Distribution of drugs PharmacokineticsJaineel Dharod
 
Biological membranes as a barriers to drugs(pH trapping)
Biological membranes as a barriers to drugs(pH trapping)Biological membranes as a barriers to drugs(pH trapping)
Biological membranes as a barriers to drugs(pH trapping)Freya Cardozo
 
Pharmakokinetics 2. myppt
Pharmakokinetics 2. mypptPharmakokinetics 2. myppt
Pharmakokinetics 2. mypptKARTHIKA K.J
 
ppt on pharmacokinetics pharmacolocy
ppt on pharmacokinetics pharmacolocy ppt on pharmacokinetics pharmacolocy
ppt on pharmacokinetics pharmacolocy AnuragSingh799
 
Pharmacokinetics, Lecture by, Dr. Baqir Naqvi.pptx
Pharmacokinetics, Lecture by, Dr. Baqir Naqvi.pptxPharmacokinetics, Lecture by, Dr. Baqir Naqvi.pptx
Pharmacokinetics, Lecture by, Dr. Baqir Naqvi.pptxDr. Baqir Raza Naqvi
 
drugintreaction-210802120hhhhhhhhhhhhhhh814 (1).pdf
drugintreaction-210802120hhhhhhhhhhhhhhh814 (1).pdfdrugintreaction-210802120hhhhhhhhhhhhhhh814 (1).pdf
drugintreaction-210802120hhhhhhhhhhhhhhh814 (1).pdfVaibhavwagh48
 
Pharmacokinetic Drug-Drug interactions
Pharmacokinetic Drug-Drug interactionsPharmacokinetic Drug-Drug interactions
Pharmacokinetic Drug-Drug interactionsAreej Abu Hanieh
 
Distribution edited
Distribution editedDistribution edited
Distribution editedmizan00
 
Protein binding unit 4 bppk pe 520 (final) [autosaved] (1)
Protein binding unit 4 bppk pe 520 (final) [autosaved] (1)Protein binding unit 4 bppk pe 520 (final) [autosaved] (1)
Protein binding unit 4 bppk pe 520 (final) [autosaved] (1)PHARMA IQ EDUCATION
 

Similar to Biopharm drug distribution.slideshare ppt (20)

Distribution of drugs Pharmacokinetics
Distribution of drugs PharmacokineticsDistribution of drugs Pharmacokinetics
Distribution of drugs Pharmacokinetics
 
Drug Distribution.pptx
Drug Distribution.pptxDrug Distribution.pptx
Drug Distribution.pptx
 
DISTRIBUTION OF DRUGS
DISTRIBUTION OF DRUGSDISTRIBUTION OF DRUGS
DISTRIBUTION OF DRUGS
 
Seminar on pharmacokinetics
Seminar on pharmacokineticsSeminar on pharmacokinetics
Seminar on pharmacokinetics
 
Biological membranes as a barriers to drugs(pH trapping)
Biological membranes as a barriers to drugs(pH trapping)Biological membranes as a barriers to drugs(pH trapping)
Biological membranes as a barriers to drugs(pH trapping)
 
Pharmakokinetics 2. myppt
Pharmakokinetics 2. mypptPharmakokinetics 2. myppt
Pharmakokinetics 2. myppt
 
Drug interaction
Drug interactionDrug interaction
Drug interaction
 
ppt on pharmacokinetics pharmacolocy
ppt on pharmacokinetics pharmacolocy ppt on pharmacokinetics pharmacolocy
ppt on pharmacokinetics pharmacolocy
 
Pharmacokinetics (1).ppt
Pharmacokinetics (1).pptPharmacokinetics (1).ppt
Pharmacokinetics (1).ppt
 
Pharmacokinetics, Lecture by, Dr. Baqir Naqvi.pptx
Pharmacokinetics, Lecture by, Dr. Baqir Naqvi.pptxPharmacokinetics, Lecture by, Dr. Baqir Naqvi.pptx
Pharmacokinetics, Lecture by, Dr. Baqir Naqvi.pptx
 
Drug distribution & clearance
Drug distribution & clearanceDrug distribution & clearance
Drug distribution & clearance
 
Pharmacokinetics
PharmacokineticsPharmacokinetics
Pharmacokinetics
 
Drug intreaction
Drug intreactionDrug intreaction
Drug intreaction
 
drugintreaction-210802120hhhhhhhhhhhhhhh814 (1).pdf
drugintreaction-210802120hhhhhhhhhhhhhhh814 (1).pdfdrugintreaction-210802120hhhhhhhhhhhhhhh814 (1).pdf
drugintreaction-210802120hhhhhhhhhhhhhhh814 (1).pdf
 
Protein binding
Protein bindingProtein binding
Protein binding
 
Pharmacokinetics revision 2021 PROF SATYA
  Pharmacokinetics revision 2021 PROF SATYA  Pharmacokinetics revision 2021 PROF SATYA
Pharmacokinetics revision 2021 PROF SATYA
 
Pharmacokinetic Drug-Drug interactions
Pharmacokinetic Drug-Drug interactionsPharmacokinetic Drug-Drug interactions
Pharmacokinetic Drug-Drug interactions
 
Distribution edited
Distribution editedDistribution edited
Distribution edited
 
Protein binding unit 4 bppk pe 520 (final) [autosaved] (1)
Protein binding unit 4 bppk pe 520 (final) [autosaved] (1)Protein binding unit 4 bppk pe 520 (final) [autosaved] (1)
Protein binding unit 4 bppk pe 520 (final) [autosaved] (1)
 
Pharmacokinitic
PharmacokiniticPharmacokinitic
Pharmacokinitic
 

More from marakiwmame

clinical pharmacokinetics slideahere final.pptx
clinical pharmacokinetics slideahere final.pptxclinical pharmacokinetics slideahere final.pptx
clinical pharmacokinetics slideahere final.pptxmarakiwmame
 
sodapdf-converted.ppt for the students 3rd
sodapdf-converted.ppt for the students 3rdsodapdf-converted.ppt for the students 3rd
sodapdf-converted.ppt for the students 3rdmarakiwmame
 
Biopharmaceutics and pharmacokinetics and diffrent aspects of the courses
Biopharmaceutics and pharmacokinetics and diffrent aspects of the coursesBiopharmaceutics and pharmacokinetics and diffrent aspects of the courses
Biopharmaceutics and pharmacokinetics and diffrent aspects of the coursesmarakiwmame
 
GI anatomy and physiology of factor affecting .pptx
GI anatomy and physiology  of factor affecting  .pptxGI anatomy and physiology  of factor affecting  .pptx
GI anatomy and physiology of factor affecting .pptxmarakiwmame
 
Unit 9 -Good manufacturing practice.pptx
Unit 9 -Good manufacturing practice.pptxUnit 9 -Good manufacturing practice.pptx
Unit 9 -Good manufacturing practice.pptxmarakiwmame
 
Unit 7-Modified Release Dosage Forms.pptx
Unit 7-Modified Release Dosage Forms.pptxUnit 7-Modified Release Dosage Forms.pptx
Unit 7-Modified Release Dosage Forms.pptxmarakiwmame
 
Unit 7-Modified Release Dosage Forms.pptx
Unit 7-Modified Release Dosage Forms.pptxUnit 7-Modified Release Dosage Forms.pptx
Unit 7-Modified Release Dosage Forms.pptxmarakiwmame
 
Unit 7-Modified Release Dosage Forms.pptx
Unit 7-Modified Release Dosage Forms.pptxUnit 7-Modified Release Dosage Forms.pptx
Unit 7-Modified Release Dosage Forms.pptxmarakiwmame
 
Unit 8- industrial pharmacy ; manufacturing of Sterile Products.pptx
Unit 8- industrial pharmacy ; manufacturing of Sterile Products.pptxUnit 8- industrial pharmacy ; manufacturing of Sterile Products.pptx
Unit 8- industrial pharmacy ; manufacturing of Sterile Products.pptxmarakiwmame
 
Unit 4- manufacturing of Capsules.industrial pharmacypdf
Unit 4- manufacturing of Capsules.industrial pharmacypdfUnit 4- manufacturing of Capsules.industrial pharmacypdf
Unit 4- manufacturing of Capsules.industrial pharmacypdfmarakiwmame
 
coatings-11-01163.pdf
coatings-11-01163.pdfcoatings-11-01163.pdf
coatings-11-01163.pdfmarakiwmame
 
Aerosols 2020 newww (2).pptx
Aerosols 2020  newww (2).pptxAerosols 2020  newww (2).pptx
Aerosols 2020 newww (2).pptxmarakiwmame
 
GMB NEW (2).pptx
GMB NEW (2).pptxGMB NEW (2).pptx
GMB NEW (2).pptxmarakiwmame
 
Physicochemical_and_biological_consideration_in_the_design_of.pptx
Physicochemical_and_biological_consideration_in_the_design_of.pptxPhysicochemical_and_biological_consideration_in_the_design_of.pptx
Physicochemical_and_biological_consideration_in_the_design_of.pptxmarakiwmame
 
ስነ ዜጋ ማስታወሻ ለ7 ክፍል.pdf
ስነ ዜጋ ማስታወሻ ለ7 ክፍል.pdfስነ ዜጋ ማስታወሻ ለ7 ክፍል.pdf
ስነ ዜጋ ማስታወሻ ለ7 ክፍል.pdfmarakiwmame
 
Tsige assignment
Tsige assignmentTsige assignment
Tsige assignmentmarakiwmame
 

More from marakiwmame (20)

clinical pharmacokinetics slideahere final.pptx
clinical pharmacokinetics slideahere final.pptxclinical pharmacokinetics slideahere final.pptx
clinical pharmacokinetics slideahere final.pptx
 
sodapdf-converted.ppt for the students 3rd
sodapdf-converted.ppt for the students 3rdsodapdf-converted.ppt for the students 3rd
sodapdf-converted.ppt for the students 3rd
 
Biopharmaceutics and pharmacokinetics and diffrent aspects of the courses
Biopharmaceutics and pharmacokinetics and diffrent aspects of the coursesBiopharmaceutics and pharmacokinetics and diffrent aspects of the courses
Biopharmaceutics and pharmacokinetics and diffrent aspects of the courses
 
GI anatomy and physiology of factor affecting .pptx
GI anatomy and physiology  of factor affecting  .pptxGI anatomy and physiology  of factor affecting  .pptx
GI anatomy and physiology of factor affecting .pptx
 
Unit 9 -Good manufacturing practice.pptx
Unit 9 -Good manufacturing practice.pptxUnit 9 -Good manufacturing practice.pptx
Unit 9 -Good manufacturing practice.pptx
 
Unit 7-Modified Release Dosage Forms.pptx
Unit 7-Modified Release Dosage Forms.pptxUnit 7-Modified Release Dosage Forms.pptx
Unit 7-Modified Release Dosage Forms.pptx
 
Unit 7-Modified Release Dosage Forms.pptx
Unit 7-Modified Release Dosage Forms.pptxUnit 7-Modified Release Dosage Forms.pptx
Unit 7-Modified Release Dosage Forms.pptx
 
Unit 7-Modified Release Dosage Forms.pptx
Unit 7-Modified Release Dosage Forms.pptxUnit 7-Modified Release Dosage Forms.pptx
Unit 7-Modified Release Dosage Forms.pptx
 
Unit 8- industrial pharmacy ; manufacturing of Sterile Products.pptx
Unit 8- industrial pharmacy ; manufacturing of Sterile Products.pptxUnit 8- industrial pharmacy ; manufacturing of Sterile Products.pptx
Unit 8- industrial pharmacy ; manufacturing of Sterile Products.pptx
 
Unit 4- manufacturing of Capsules.industrial pharmacypdf
Unit 4- manufacturing of Capsules.industrial pharmacypdfUnit 4- manufacturing of Capsules.industrial pharmacypdf
Unit 4- manufacturing of Capsules.industrial pharmacypdf
 
coatings-11-01163.pdf
coatings-11-01163.pdfcoatings-11-01163.pdf
coatings-11-01163.pdf
 
shao2003.pdf
shao2003.pdfshao2003.pdf
shao2003.pdf
 
Aerosols 2020 newww (2).pptx
Aerosols 2020  newww (2).pptxAerosols 2020  newww (2).pptx
Aerosols 2020 newww (2).pptx
 
GMB NEW (2).pptx
GMB NEW (2).pptxGMB NEW (2).pptx
GMB NEW (2).pptx
 
Physicochemical_and_biological_consideration_in_the_design_of.pptx
Physicochemical_and_biological_consideration_in_the_design_of.pptxPhysicochemical_and_biological_consideration_in_the_design_of.pptx
Physicochemical_and_biological_consideration_in_the_design_of.pptx
 
ስነ ዜጋ ማስታወሻ ለ7 ክፍል.pdf
ስነ ዜጋ ማስታወሻ ለ7 ክፍል.pdfስነ ዜጋ ማስታወሻ ለ7 ክፍል.pdf
ስነ ዜጋ ማስታወሻ ለ7 ክፍል.pdf
 
cirtificate.pdf
cirtificate.pdfcirtificate.pdf
cirtificate.pdf
 
3455674.ppt
3455674.ppt3455674.ppt
3455674.ppt
 
dagnipdf.pdf
dagnipdf.pdfdagnipdf.pdf
dagnipdf.pdf
 
Tsige assignment
Tsige assignmentTsige assignment
Tsige assignment
 

Recently uploaded

Forensic medicine MCQ for early learners
Forensic medicine MCQ for early learnersForensic medicine MCQ for early learners
Forensic medicine MCQ for early learnersAlaguPandi5
 
JOURNAL CLUB PRESENTATION TEMPLATE DOCUMENT
JOURNAL CLUB PRESENTATION TEMPLATE DOCUMENTJOURNAL CLUB PRESENTATION TEMPLATE DOCUMENT
JOURNAL CLUB PRESENTATION TEMPLATE DOCUMENTThomas Onyango Kirengo
 
Mgr university bsc nursing adult health previous question paper with answers
Mgr university  bsc nursing adult health previous question paper with answersMgr university  bsc nursing adult health previous question paper with answers
Mgr university bsc nursing adult health previous question paper with answersShafnaP5
 
High Purity 99% PMK Ethyl Glycidate Powder CAS 28578-16-7
High Purity 99% PMK Ethyl Glycidate Powder CAS 28578-16-7High Purity 99% PMK Ethyl Glycidate Powder CAS 28578-16-7
High Purity 99% PMK Ethyl Glycidate Powder CAS 28578-16-7grandmotherprocess99
 
Failure to thrive in neonates and infants + pediatric case.pptx
Failure to thrive in neonates and infants  + pediatric case.pptxFailure to thrive in neonates and infants  + pediatric case.pptx
Failure to thrive in neonates and infants + pediatric case.pptxclaviclebrown44
 
Histology of Epithelium - Dr Muhammad Ali Rabbani - Medicose Academics
Histology of Epithelium - Dr Muhammad Ali Rabbani - Medicose AcademicsHistology of Epithelium - Dr Muhammad Ali Rabbani - Medicose Academics
Histology of Epithelium - Dr Muhammad Ali Rabbani - Medicose AcademicsMedicoseAcademics
 
Creeping Stroke - Venous thrombosis presenting with pc-stroke.pptx
Creeping Stroke - Venous thrombosis presenting with pc-stroke.pptxCreeping Stroke - Venous thrombosis presenting with pc-stroke.pptx
Creeping Stroke - Venous thrombosis presenting with pc-stroke.pptxYasser Alzainy
 
Unveiling Alcohol Withdrawal Syndrome: exploring it's hidden depths
Unveiling Alcohol Withdrawal Syndrome: exploring it's hidden depthsUnveiling Alcohol Withdrawal Syndrome: exploring it's hidden depths
Unveiling Alcohol Withdrawal Syndrome: exploring it's hidden depthsYash Garg
 
Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...
Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...
Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...Health Kinesiology Natural Bioenergetics
 
ESC HF 2024 Spotlights Day-2.pptx heart failure
ESC HF 2024 Spotlights Day-2.pptx heart failureESC HF 2024 Spotlights Day-2.pptx heart failure
ESC HF 2024 Spotlights Day-2.pptx heart failuremahiavy26
 
TEST BANK For Porth's Essentials of Pathophysiology, 5th Edition by Tommie L ...
TEST BANK For Porth's Essentials of Pathophysiology, 5th Edition by Tommie L ...TEST BANK For Porth's Essentials of Pathophysiology, 5th Edition by Tommie L ...
TEST BANK For Porth's Essentials of Pathophysiology, 5th Edition by Tommie L ...rightmanforbloodline
 
How to buy 5cladba precursor raw 5cl-adb-a raw material
How to buy 5cladba precursor raw 5cl-adb-a raw materialHow to buy 5cladba precursor raw 5cl-adb-a raw material
How to buy 5cladba precursor raw 5cl-adb-a raw materialSherrylee83
 
supply cas 5449-12-7 BMK glycidic acid(powder) in stock EU pick-up
supply cas 5449-12-7 BMK glycidic acid(powder) in stock EU pick-upsupply cas 5449-12-7 BMK glycidic acid(powder) in stock EU pick-up
supply cas 5449-12-7 BMK glycidic acid(powder) in stock EU pick-upSherrylee83
 
Lachesis Mutus- a Homoeopathic medicinel.pptx
Lachesis Mutus- a Homoeopathic medicinel.pptxLachesis Mutus- a Homoeopathic medicinel.pptx
Lachesis Mutus- a Homoeopathic medicinel.pptxMUHAMMADZAHID314
 
Benefits of Chanting Hanuman Chalisa .pdf
Benefits of Chanting Hanuman Chalisa .pdfBenefits of Chanting Hanuman Chalisa .pdf
Benefits of Chanting Hanuman Chalisa .pdfLearnyoga
 
Difference Between Skeletal Smooth and Cardiac Muscles
Difference Between Skeletal Smooth and Cardiac MusclesDifference Between Skeletal Smooth and Cardiac Muscles
Difference Between Skeletal Smooth and Cardiac MusclesMedicoseAcademics
 
SEMESTER-V CHILD HEALTH NURSING-UNIT-1-INTRODUCTION.pdf
SEMESTER-V CHILD HEALTH NURSING-UNIT-1-INTRODUCTION.pdfSEMESTER-V CHILD HEALTH NURSING-UNIT-1-INTRODUCTION.pdf
SEMESTER-V CHILD HEALTH NURSING-UNIT-1-INTRODUCTION.pdfSachin Sharma
 
Anti viral drug pharmacology classification
Anti viral drug pharmacology classificationAnti viral drug pharmacology classification
Anti viral drug pharmacology classificationNikitaPawar41153
 
parliaments-for-health-security_RecordOfAchievement.pdf
parliaments-for-health-security_RecordOfAchievement.pdfparliaments-for-health-security_RecordOfAchievement.pdf
parliaments-for-health-security_RecordOfAchievement.pdfDr. Nasir Mustafa
 
Negative Pressure Wound Therapy in Diabetic Foot Ulcer.pptx
Negative Pressure Wound Therapy in Diabetic Foot Ulcer.pptxNegative Pressure Wound Therapy in Diabetic Foot Ulcer.pptx
Negative Pressure Wound Therapy in Diabetic Foot Ulcer.pptxAdhithya Mullath Ullas
 

Recently uploaded (20)

Forensic medicine MCQ for early learners
Forensic medicine MCQ for early learnersForensic medicine MCQ for early learners
Forensic medicine MCQ for early learners
 
JOURNAL CLUB PRESENTATION TEMPLATE DOCUMENT
JOURNAL CLUB PRESENTATION TEMPLATE DOCUMENTJOURNAL CLUB PRESENTATION TEMPLATE DOCUMENT
JOURNAL CLUB PRESENTATION TEMPLATE DOCUMENT
 
Mgr university bsc nursing adult health previous question paper with answers
Mgr university  bsc nursing adult health previous question paper with answersMgr university  bsc nursing adult health previous question paper with answers
Mgr university bsc nursing adult health previous question paper with answers
 
High Purity 99% PMK Ethyl Glycidate Powder CAS 28578-16-7
High Purity 99% PMK Ethyl Glycidate Powder CAS 28578-16-7High Purity 99% PMK Ethyl Glycidate Powder CAS 28578-16-7
High Purity 99% PMK Ethyl Glycidate Powder CAS 28578-16-7
 
Failure to thrive in neonates and infants + pediatric case.pptx
Failure to thrive in neonates and infants  + pediatric case.pptxFailure to thrive in neonates and infants  + pediatric case.pptx
Failure to thrive in neonates and infants + pediatric case.pptx
 
Histology of Epithelium - Dr Muhammad Ali Rabbani - Medicose Academics
Histology of Epithelium - Dr Muhammad Ali Rabbani - Medicose AcademicsHistology of Epithelium - Dr Muhammad Ali Rabbani - Medicose Academics
Histology of Epithelium - Dr Muhammad Ali Rabbani - Medicose Academics
 
Creeping Stroke - Venous thrombosis presenting with pc-stroke.pptx
Creeping Stroke - Venous thrombosis presenting with pc-stroke.pptxCreeping Stroke - Venous thrombosis presenting with pc-stroke.pptx
Creeping Stroke - Venous thrombosis presenting with pc-stroke.pptx
 
Unveiling Alcohol Withdrawal Syndrome: exploring it's hidden depths
Unveiling Alcohol Withdrawal Syndrome: exploring it's hidden depthsUnveiling Alcohol Withdrawal Syndrome: exploring it's hidden depths
Unveiling Alcohol Withdrawal Syndrome: exploring it's hidden depths
 
Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...
Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...
Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...
 
ESC HF 2024 Spotlights Day-2.pptx heart failure
ESC HF 2024 Spotlights Day-2.pptx heart failureESC HF 2024 Spotlights Day-2.pptx heart failure
ESC HF 2024 Spotlights Day-2.pptx heart failure
 
TEST BANK For Porth's Essentials of Pathophysiology, 5th Edition by Tommie L ...
TEST BANK For Porth's Essentials of Pathophysiology, 5th Edition by Tommie L ...TEST BANK For Porth's Essentials of Pathophysiology, 5th Edition by Tommie L ...
TEST BANK For Porth's Essentials of Pathophysiology, 5th Edition by Tommie L ...
 
How to buy 5cladba precursor raw 5cl-adb-a raw material
How to buy 5cladba precursor raw 5cl-adb-a raw materialHow to buy 5cladba precursor raw 5cl-adb-a raw material
How to buy 5cladba precursor raw 5cl-adb-a raw material
 
supply cas 5449-12-7 BMK glycidic acid(powder) in stock EU pick-up
supply cas 5449-12-7 BMK glycidic acid(powder) in stock EU pick-upsupply cas 5449-12-7 BMK glycidic acid(powder) in stock EU pick-up
supply cas 5449-12-7 BMK glycidic acid(powder) in stock EU pick-up
 
Lachesis Mutus- a Homoeopathic medicinel.pptx
Lachesis Mutus- a Homoeopathic medicinel.pptxLachesis Mutus- a Homoeopathic medicinel.pptx
Lachesis Mutus- a Homoeopathic medicinel.pptx
 
Benefits of Chanting Hanuman Chalisa .pdf
Benefits of Chanting Hanuman Chalisa .pdfBenefits of Chanting Hanuman Chalisa .pdf
Benefits of Chanting Hanuman Chalisa .pdf
 
Difference Between Skeletal Smooth and Cardiac Muscles
Difference Between Skeletal Smooth and Cardiac MusclesDifference Between Skeletal Smooth and Cardiac Muscles
Difference Between Skeletal Smooth and Cardiac Muscles
 
SEMESTER-V CHILD HEALTH NURSING-UNIT-1-INTRODUCTION.pdf
SEMESTER-V CHILD HEALTH NURSING-UNIT-1-INTRODUCTION.pdfSEMESTER-V CHILD HEALTH NURSING-UNIT-1-INTRODUCTION.pdf
SEMESTER-V CHILD HEALTH NURSING-UNIT-1-INTRODUCTION.pdf
 
Anti viral drug pharmacology classification
Anti viral drug pharmacology classificationAnti viral drug pharmacology classification
Anti viral drug pharmacology classification
 
parliaments-for-health-security_RecordOfAchievement.pdf
parliaments-for-health-security_RecordOfAchievement.pdfparliaments-for-health-security_RecordOfAchievement.pdf
parliaments-for-health-security_RecordOfAchievement.pdf
 
Negative Pressure Wound Therapy in Diabetic Foot Ulcer.pptx
Negative Pressure Wound Therapy in Diabetic Foot Ulcer.pptxNegative Pressure Wound Therapy in Diabetic Foot Ulcer.pptx
Negative Pressure Wound Therapy in Diabetic Foot Ulcer.pptx
 

Biopharm drug distribution.slideshare ppt

  • 1. DRUG DISTRIBUTION Asnake W.(B.Pharm, MSc in Pharmaceutics)
  • 2. DRUG DISTRIBUTION…  Is reversible transfer of a drug to and from the site of measurement (blood or plasma).  It is the passage of drug from the circulation to the tissue and site of its action.  Low plasma binding or high tissue binding or high lipophilicity usually means an extensive tissue distribution 5/7/2024 Phar 412 by Asnake W. (B Phar, MSc) 2
  • 3. DRUG DISTRIBUTION… 5/7/2024 Phar 412 by Asnake W. (B Phar, MSc) 3  In pharmacokinetics, the distribution is described by the parameter V, the apparent volume of distribution.  Volume of plasma in which the total amount of drug in the body would be required to be dissolved in order to reflect the drug concentration attained in plasma. Affects The half life of the drug and The fluctuation of the concentration at steady state.
  • 4. Factors affecting drug distribution 5/7/2024 Phar 412 by Asnake W. (B Phar, MSc) 4  Extent/rate of drug distribution 1. Membrane permeability 2. Blood perfusion 3. Lipid solubility 4. PH-PKA 5. Plasma protein binding 6. Tissue drug binding
  • 5. Factors affecting drug distribution 5/7/2024 Phar 412 by Asnake W. (B Phar, MSc) 5 1.Membrane permeability  Capillary walls are quite permeable  Lipid soluble drugs pass through very rapidly  Water soluble compounds penetrate more slowly at a rate more dependent on their size. Plasma membrane barrier and drug diffusion across it
  • 6. Factors affecting drug distribution 5/7/2024 Phar 412 by Asnake W. (B Phar, MSc) 6  There are deviations to the typical capillary structure I. Permeability is greatly increased in the renal capillaries - by pores in the membrane of the endothelial cells, II. in specialized hepatic capillaries, known as sinusoids -may lack a complete lining. results in more extension distribution of many drugs
  • 7. Factors affecting drug distribution 5/7/2024 Phar 412 by Asnake W. (B Phar, MSc) 7 III. Brain capillaries  restrict the transfer of molecules from blood to brain tissue.  Lipid soluble compounds can be readily transferred  This is the basis of the "blood-brain“ barrier. Thiopental vs pencillin, Levodopa vs dopamine
  • 8. 5/7/2024 Phar 412 by Asnake W. (B Phar, MSc) 8 2. Blood perfusion rate The rate at which blood perfuses to different organs varies widely Factors affecting drug distribution…
  • 9. Factors affecting drug distribution… 5/7/2024 Phar 412 by Asnake W. (B Phar, MSc) 9 3.Lipid Solubility  Lipid solubility will affect the ability of the drug to cross lipid membrane barriers  Very high lipid solubility can result in a drug partitioning into highly vascular lipid-rich areas.  these drugs slowly redistribute from body fat where they may remain for long periods of time.
  • 10. Factors affecting drug distribution… 5/7/2024 Phar 412 by Asnake W. (B Phar, MSc) 10 4. Effects of pH  The rate of movement of a drug out of circulation will depend on its degree of ionization and therefore its pKa.  Changes in pH occurring in disease may also affect drug distribution. E.g. blood becomes more acidic if respiration is inadequate.  Barbiturate poisoning treated by Sodium bicarbonate 5.Plasma protein binding:  Extensive plasma protein binding will cause more drug to stay in the central blood compartment.  ↑Strong proteinbinding=↓V
  • 11. Blood proteins to which drugs bind 5/7/2024 Phar 412 by Asnake W. (B Phar, MSc) 11 Protein Molecular Weight Concentration (g%) Drugs that bind Human Serum Albumin 65,000 3.5-5.0 Large variety of drugs a1-Acid Glycoprotein 44,000 0.04-0.1 Basic drugs such as imipramine, lidocaine, quinidine, etc. Lipoproteins 200,000 to 3,400,000 Variable Basic, lipophilic drugs like chlorpromazine a1-Globulin 59,000 0.003-0.007 Steroids like corticosterone, and thyroxine and cyanocobalamin a2-Globulin 1,34,000 0.015-0.06 Vitamins A, D, E and K and cupric ions Haemoglobin 64,500 11-16 Phenytoin, pentobarbital, and phenothiazines
  • 12. Factors affecting drug distribution… 5/7/2024 Phar 412 by Asnake W. (B Phar, MSc) 12 What is the effect of protein binding on drug action? Extensive plasma protein binding will...decrease peak plasma level.  Elimination of a highly bound drug may be delayed -drug elimination by metabolism and excretion will be delayed. responsible for prolonging the effect of the drug
  • 13. Factors affecting drug distribution… 5/7/2024 Phar 412 by Asnake W. (B Phar, MSc) 13  A low plasma protein level may occur in: -old age -malnutrition  Illness such as liver disease, chronic renal failure where there is excessive excretion of albumin.  In each case the result is a smaller proportion of drug in bound form and more free drug in the plasma.  able to produce a greater therapeutic effect
  • 14. Factors affecting drug distribution (Cont.): 5/7/2024 Phar 412 by Asnake W. (B Phar, MSc) 14 6. Tissue drug binding (tissue localization of drugs):  Drugs may bind to intracellular molecules  The affinity of a tissue for a drug may be due to: binding to tissue proteins or to nucleic acids, dissolution in the lipid e.g. The concentration of chloroquine in the liver is due to the binding of the drug to DNA. e.g. Barbiturates distribute extensively into adipose tissue, b/c of lipid solubility e.g. Tetracycline bind to bone thus should be avoided in young children or discoloration of permanent teeth may occur
  • 15. (Cont.): 5/7/2024 Phar 412 by Asnake W. (B Phar, MSc) 15  Other distribution considerations A. Body composition of the very young and the very old may be quite different from 'normal’ Eg. Total body water( more in infants), Fat content (elder), BBB( infants), Plasma protein content ( infants and adults) A. The obese patients –large adipose tissue than body water • Drugs which are relatively polar has volume of distribution values may be lower than normal. • apparent volume of distribution of antipyrine is 0.62l/kg in normal weight subjects but 0.46l/kg in obese patients • digoxin and gentamicin are also quite polar
  • 16. Drug metabolism Phar 412 by Asnake W. (B Phar, MSc) 16 Def. The irreversible biotransformation of drug in the body  Drug metabolism often converts lipophilic chemical compounds into:  more hydrophilic, more water soluble  have their actions decreased (become less effective) phenytoin to p-hydroxy phenytoin  increased (become more effective) eg enalapril to enalaprilat  Equal activity: eg phenylbutazone to oxyphenbutazone  May be converted to less toxic or more toxic metabolites
  • 17. Drug metabolism 5/7/2024 Phar 412 by Asnake W. (B Phar, MSc) 17
  • 18. Drug metabolism… 5/7/2024 Phar 412 by Asnake W. (B Phar, MSc) 18  The metabolism of drugs takes place mainly in the liver (the smooth endoplasmic reticulum of the liver cell).  However, kidney, lung, intestine and placenta can also be involved in this process  Occasionally the metabolite is less water soluble.  Example is the acetyl metabolite of some of the sulfonamides. -Precipitated in urine, crystalluria.
  • 19. Drug metabolism 5/7/2024 Phar 412 by Asnake W. (B Phar, MSc) 19
  • 20. Drug metabolism 5/7/2024 Phar 412 by Asnake W. (B Phar, MSc) 20
  • 21. Phases of metabolism: 5/7/2024 Phar 412 by Asnake W. (B Phar, MSc) 21 Phase I reactions:  Change drugs to more hydrophilic metabolites -more readily excreted  Introduce into the drug molecule sites for phase II reactions  May be less toxic (but not always)  Mostly occur in the endoplasmic reticulum (microsomes) of liver cells.  Usually involve oxidation, reduction, hydrolysis or other reactions ( Reading assignments)
  • 22. Phase two reactions 5/7/2024 Phar 412 by Asnake W. (B Phar, MSc) 22 Conjugation  Conjugation reactions covalently add large, polar endogenous molecules to parent drug or Phase I metabolite →inactive and excretable  (glucuronide, glutathione, sulfate, acetate, amino acids etc)  Readly avaliable, can combine easily, in close association with the microsomal mixed function oxidases
  • 23. Phases of metabolism… 5/7/2024 Phar 412 by Asnake W. (B Phar, MSc) 23 Glucuronidation  This is the main conjugation reaction in the body. -Readily available source of conjugating moiety -viz. alcohols, acids, amines, etc. can combine easily -All mammals have the common ability to produce glucuronides -The glucuronidation enzymes are in close association with the microsomal mixed function oxidases -glucuronidation can take place in most body tissues
  • 24. Phases of metabolism… 5/7/2024 Phar 412 by Asnake W. (B Phar, MSc) 24 I. Induction  Induction ~ ↑ metabolic activity of enzyme = ↓ [drug] E.g. Phenobarbitone will induce the metabolism of itself, phenytoin, warfarin, etc. E.g. Cigarette smoking can cause increased elimination of theophylline. E.g. alcohol  Dosing rates may need to be increased to maintain effective plasma concentrations
  • 25. Phases of metabolism… 5/7/2024 Phar 412 by Asnake W. (B Phar, MSc) 25 II. Inhibition  Inhibition ~ ↓ metabolic activity of enzyme = ↑ [drug] e.g. grape fruit juice  For example, warfarin inhibits tolbutamide elimination which can lead to the accumulation of drug.  Cimetidine is a therapeutic agent that has been found to impair the in vivo metabolism of other drugs
  • 26. Diseases and Drug Metabolism: 5/7/2024 Phar 412 by Asnake W. (B Phar, MSc) 26 Liver Disease:  Acute or chronic diseases that affect liver function markedly affect hepatic metabolism of some drugs.  fat accumulation, alcoholic cirrhosis, biliary cirrhosis, and acute viral or drug hepatitis.  may impair hepatic drug-metabolizing enzymes, and thereby markedly affect drug elimination.  Eg., The half-life of diazepam inpatients with liver cirrhosis or acute viral hepatitis is greatly increased, with a corresponding prolongation of its effect. Cardiac Disease:  Cardiac disease, by limiting blood flow to the liver may impair disposition of those drugs whose metabolism is flow-limited.
  • 27. Excretion 5/7/2024 Phar 412 by Asnake W. (B Phar, MSc) 27
  • 28. Excretion… 5/7/2024 Phar 412 by Asnake W. (B Phar, MSc) 28
  • 29. Excretion 5/7/2024 Phar 412 by Asnake W. (B Phar, MSc) 29 1. Glomerular filtration 2. Active tubular secretion 3. passive tubular reabsorption
  • 30. 1. Glomerular filtration 5/7/2024 Phar 412 by Asnake W. (B Phar, MSc) 30  In the glomerulus all molecules (including drugs) of low molecular weight (less than 2000) are radially filtered out of the blood unless they are tightly bounded to plasma protein (Albumin).  GF and ATS tend to increase the concentration of drugs in lumen and hence facilitate excretion whereas tubular reabsorption decreases it and prevents the movement of drug out of the body.  The driving force is the hydrostatic pressure, 120 to 130 ml/min is filtered through the glomeruli, the rate being called as the glomerular filtration rate (GFR).  Creatinine, inulin, mannitol and sodium thiosulphate are used to estimate GFR.
  • 31. 2. Active tubular secretion 5/7/2024 Phar 412 by Asnake W. (B Phar, MSc) 31 It is a carrier-mediated process which requires energy against the for transportation of compounds against concentration gradient. The system is capacity-limited and saturable. System for secretion of organic acids/anions like penicillins, salicylates, glucuronides, sulphates, and uric acid are secreted. System for secretion of organic bases/cations like morphine, mecamylamine, hexamethonium and endogenous amines such as catecholamines, choline, histamine, etc. Drugs undergoing active secretion have excretion rate values greater than the normal GFR value.
  • 32. 3. Tubular reabsorption 5/7/2024 Phar 412 by Asnake W. (B Phar, MSc) 32  In the distal tubule there is passive excretion and re-absorption of lipid soluble drugs. Filtered lipophilic drugs are extensively reabsorbed. Thus if a drug is non-ionized or in the unionized form it maybe readily reabsorbed. Many drugs are either weak bases or acids and therefore the ph of the filtrate can greatly influence the extent of tubular re absorpation for many drugs.
  • 33. Drug excretion 5/7/2024 Phar 412 by Asnake W. (B Phar, MSc) 33
  • 34. Drug Excretion… 5/7/2024 Phar 412 by Asnake W. (B Phar, MSc) 34 Renal clearance:  Clearance is defined as the hypothetical volume of body fluids containing drug from which the drug is removed or cleared completely in a specific period of time  quantitatively describing the renal excretion of drugs  used to investigate the mechanism of drug excretion: A. if the drug is filtered but not secreted or reabsorbed the renal clearance will be about 120ml/min in normal subjects. B. If the renal clearance is less than 120ml/m in then we can assume that at least two processes are in operation, glomerular filtration and tubular re-absorption. C. If the renal clearance is greater than 120ml/m in then tubular secretion must be contributing to the elimination process
  • 35. Drug excretion 5/7/2024 Phar 412 by Asnake W. (B Phar, MSc) 35
  • 36. Renal drug clearance is lower in: 5/7/2024 Phar 412 by Asnake W. (B Phar, MSc) 36 Elderly and Newborn Women (20%) than men Kidney and Heart Disease Patients taking drugs which block secretion (aspirin, probenecid)
  • 37. CONT… Phar 412 by Asnake W. (B Phar, MSc) 37 2.Fecal excretion:  Elimination of toxicants in the feces  Occurs from two processes: A-excretion in bile:  Some heavy metals are excreted in the bile, e.g., arsenic, lead, and mercury.  However, the most likely substances to be excreted via the bile are comparatively large, ionized molecules, such as large molecular weight (greater than 300) conjugates e.g. morphine and chloramphenicol, indomethacin (as glucuronide, glutathione).  The biliary secretion is active  There can also be competition between compounds
  • 38. Drug excretion… Phar 412 by Asnake W. (B Phar, MSc) 38  Since most of the substances excreted in the bile are water-soluble not likely to be reabsorbed as such.  However, enzymes in the intestinal flora hydrolyzing some glucuronide and sulfate conjugates less-polar compounds that may then be reabsorbed.  This process is known as the entero-hepatic circulation. prolong the life of the drug in the body
  • 39. Drug excretion… 5/7/2024 Phar 412 by Asnake W. (B Phar, MSc) 39  Another way that drugs can be eliminated via the feces is by: B-direct intestinal excretion:  Orally administered drugs may be excreted in the feces if they are incompletely absorbed or not absorbed at all (e.g. Cholestyramine)  Increasing the lipid content of the intestinal tract can enhance intestinal excretion of some lipophilic substances.
  • 40. Drug excretion… 5/7/2024 Phar 412 by Asnake W. (B Phar, MSc) 40  For this reason, mineral oil is some times added to the diet to help eliminate toxic substances, which are known to be excreted directly into the intestinal tract  Drugs may be excreted by passive diffusion from: 3.Pulmonary excretion:  The lung is the major organ of excretion for gaseous and volatile substances.  Most of the gaseous anesthetics are extensively eliminated in expired air.
  • 41. 4.Salivary excretion 5/7/2024 Phar 412 by Asnake W. (B Phar, MSc) 41  Drug excretion into saliva appears to be dependent on pH partition and protein binding.  Basic drugs are excreted more in saliva as compared to acidic drugs e.g. caffeine, theophylline, phenytoin, carbamazepine, etc  In some instances, salivary secretion is responsible for localized side effects
  • 42. Drug excretion 5/7/2024 Phar 412 by Asnake W. (B Phar, MSc) 42  E.g. Excretion of antibiotics may cause black hairy tongue, -Super infection from antibiotics. -Dental mottling upon tetracycline ingestion. 5.Skin excretion:- is responsible to some extent for the urticaria and dermatitis and other hypersensitivity reactions. Iodine, bromine, benzoic acid, salicylic acid, lead, arsenic mercury, iron and alcohol are examples of compounds that excreted in sweat
  • 43. Drug excretion… 5/7/2024 Phar 412 by Asnake W. (B Phar, MSc) 43 6. Mammary excretion:  Both a-basic substances and lipid-soluble compounds can be excreted into milk. -milk is more acidic than blood plasma. -milk contains 3-4% lipids,  lipid-soluble drugs can diffuse along with fats from plasma into the mammary gland.  Substances that are chemically similar to calcium can also be excreted into milk along with calcium  Ethanol and tetracycline enter the milk by diffusion through membrane pores( of mammary alveolar cells).  some potent drugs such as barbiturates, morphine and ergotamine may induce toxicity in infants
  • 44. Ends & ??? 5/7/2024 Phar 412 by Asnake W. (B Phar, MSc) 44

Editor's Notes

  1. How V can affect the half-life of a drug and the fluctuation of concentration at steady state. 1. Half-life: The volume of distribution (V) is a pharmacokinetic parameter that describes the apparent space in the body available to contain the total amount of drug. It is calculated as the ratio of the amount of drug in the body to the concentration of the drug in the plasma. A larger volume of distribution indicates that the drug is distributed extensively into tissues beyond the plasma, while a smaller volume of distribution suggests that the drug remains predominantly in the plasma. The half-life of a drug is influenced by its volume of distribution. Generally, drugs with a larger volume of distribution tend to have a longer half-life. This is because a larger volume of distribution indicates that a significant amount of the drug is distributed into tissues, which can lead to slower elimination. On the other hand, drugs with a smaller volume of distribution are typically cleared more rapidly from the body, resulting in a shorter half-life. 2. Fluctuation of concentration at steady state: The volume of distribution also affects the fluctuation of drug concentration at steady state. When a drug is administered at regular intervals, it reaches a steady state where the rate of drug administration equals the rate of drug elimination. At steady state, the fluctuation of drug concentration around the average concentration depends on the volume of distribution. A larger volume of distribution generally leads to smaller fluctuations in drug concentration at steady state. This is because a larger volume of distribution implies that a greater amount of drug is distributed throughout the body, resulting in a more even distribution of drug concentration. On the other hand, a smaller volume of distribution can lead to larger fluctuations in drug concentration at steady state, as the drug remains primarily in the plasma and is subject to changes in dosing and elimination. It's important to note that while the volume of distribution can influence the half-life and concentration fluctuation, these relationships are not absolute and can be influenced by other factors such as drug clearance, metabolism, and binding to plasma proteins or tissues. Additionally, individual variations and specific drug characteristics may further modify these relationships.
  2. Protein binding plays a crucial role in drug action and pharmacokinetics. When a drug is administered, it can bind to proteins present in the blood plasma, such as albumin and alpha-1 acid glycoprotein. The extent of protein binding affects the drug's distribution, elimination, and overall therapeutic effect. Here are the effects of protein binding on drug action: 1. Decrease in peak plasma level: Drugs that exhibit extensive plasma protein binding have a smaller fraction of unbound (free) drug available in the bloodstream. Only the unbound fraction of a drug is typically pharmacologically active and able to distribute into tissues. Therefore, when a drug is highly bound to plasma proteins, the peak plasma level of the free (active) drug will be lower than if the drug had minimal binding. This can affect the drug's onset of action and peak therapeutic effect. 2. Delayed elimination: Highly protein-bound drugs tend to have slower elimination from the body. Since only the unbound fraction of a drug is available for metabolism and excretion, the bound fraction remains in the bloodstream and tissues for longer periods. As a result, the elimination of a highly protein-bound drug may be delayed, leading to a longer half-life and a prolonged duration of action. 3. Prolonged drug effect: Protein binding, especially when it is extensive, can contribute to prolonging the effect of certain drugs. For example, digoxin, a cardiac glycoside, is highly bound to plasma proteins. This binding slows down the elimination of digoxin, resulting in an extended duration of action and a prolonged therapeutic effect on the heart. Monitoring the levels of protein-bound drugs in the blood is important to maintain therapeutic efficacy and avoid toxicity. It's worth noting that drug-protein binding interactions can also have additional implications, such as drug interactions and the potential for displacement of one drug from protein binding sites by another. These factors can further influence drug action, distribution, and elimination.